Table 4.

Analysis of the study population stratified by HAART use, TLC, anemia, and CD4 count.

Variable	CD4 counts			P-value
	Stage 3 (0–199)	Stage 2 (200–499)	Stage 1 (≥500)
HAART naive
TLC
<1.0	54 (91.5)	4 (6.8)	1 (1.7)	0.000
1.0–2.0	70 (50.0)	58 (41.4)	12 (8.6)	0.000
>2.0	24 (27.6)	42 (48.3)	21 (24.1)	0.000
Anemia
9.5–10.5	44 (64.7)	18 (26.5)	6 (8.4)	0.000
8.0–9.4	26 (59.1)	16 (36.4)	2 (4.5)	0.000
6.5–7.9	24 (60.0)	13 (32.5)	3 (7.5)	0.000
<6.5	27 (77.1)	7 (20.0)	1 (2.9)	0.000
On HAART
TLC
<1.0	4 (15.4)	19 (70.1)	3 (11.5)	0.000
1.0–2.0	21 (36.8)	26 (45.6)	10 (17.5)	0.005
>2.0	11 (12.5)	50 (56.8)	21 (23.9)
Anaemia
9.5–10.5	5 (10.9)	32 (69.6)	9 (19.6)	0.000
8.0–9.4	6 (40.0)	8 (53.3)	1 (6.7)	0.020
6.5–7.9	0	0	0
<6.5	0	0	0